Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903

HIV Medicine

Volumn 7, Issue 7, 2006, Pages 442-450

  Margot, N A ^a   Lu, B ^a   Cheng, A ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Clinical trials; K65R; Renofovir; Resistance

Indexed keywords

EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; FREQUENCY ANALYSIS; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; TREATMENT DURATION;

ADENINE; BENZOXAZINES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TREATMENT OUTCOME;

EID: 33747646240     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00404.x     Document Type: Article

References (34)

1. Naesens L, Snoeck R, Andrei G et al. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8: 1-23.
2. Arimilli M, Kim C, Bischofberger N. Synthesis, in vitro biological evaluation and oral bioavailability of 9-[2-(phosphonomethoxy) propyl]adenine (PMPA) prodrugs. Antiviral Chem Chemother 1997; 8: 557-564.
3. Naesens L, Bischofberger N, Augustijns P et al. Antiretroviral efficacy and pharmacokinetics of oral bis (isopropyloxycarbonyloxymethyl)-9 (2-phosphonylmethoxypropyl) adenine in mice. Antimicrob Agents Chemother 1998; 42: 1568-1573.
4. Wainberg MA, Miller MD, Quan Y et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antiviral Ther 1999; 4: 87-94.
5. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 1999; 179: 92-100.
6. Gu Z, Gao Q, Fang H et al. Identification of a mutation of codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1994; 38: 275-281.
7. Zhang D, Caliendo AM, Eron JJ et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994; 38: 282-287.
8. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997; 41: 1094-1098.
9. De Antoni A, Foli A, Lisziewicz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997; 176: 899-903.
10. Winters MA, Shafer RW, Jellinger RA et al. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother 1997; 41: 757-762.
11. Harrigan PR, Stone C, Griffin P et al. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J Infect Dis 2000; 181: 912-920.
12. Miller V, Ait-Khaled M, Stone C et al. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000; 14: 163-171.
13. Garcia-Lerma JG, MacInnes H, Bennett D et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol 2003; 77: 5685-5693.
14. Miller MD, Margot N, Lu B et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837-846.
15. Margot NA, Isaacson E, McGowan I et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227-1235.
16. Masquelier B, Tamalet C, Montes B et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antiviral Ther 2004; 9: 315-323.
17. Barditch-Crovo P, Deeks SG, Collier A et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 2001; 45: 2733-2739.
18. McColl DJ, Margot NA, Wulfsoh M et al. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr Hum Retrovirol 2004; 37: 1340-1349.
19. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr Hum Retrovirol 2003; 33: 15-21.
20. Jemsek J, Harper E, Hutcherson P. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once-daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Oral Presentation 51].
21. Gallant JE, Rodriguez A, Weinberg W et al. Early virologic non-response to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192: 1921-1930.
22. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. J Am Med Assoc 2004; 292: 191-201.
23. Miller MD, Margot NA, McColl DJ et al. Characterization of resistance mutation patterns emerging over 2 years during first-line antiretroviral treatment with tenofovir DF or stavudine in combination with lamivudine and efavirenz. Antiviral Ther 2003; 8: S151.
24. McColl DJ, Parkin NT, Miller MD. Characterization of patient-derived HIV-1 isolates containing the L74V or K65R mutations in reverse transcriptase. 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 2004 [Poster 393].
25. Deval J, White KL, Miller MD et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279: 509-516.
26. Delaugerre C, Roudiere L, Peytavin G et al. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol 2005; 32: 241-244.
27. Rodriguez-French A, Boghossian J, Gray GE et al. The NEAT study: A 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 2004; 35: 22-32.
28. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-480.
29. Barbour JD, Wrin T, Grant RM et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002; 76: 11104-11112.
30. Landman R, Descamps D, Trylesinski A et al. Successful rescue therapy in patients developing K65R on tenofovir containing regimens: Long-term follow-up. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005 [Abstract 710].
31. Gallant JE, Rodriguez AE, Weinberg W et al. Efficacy of once-daily abacavir/lamivudine fixed-dose combination (ABC/3TC) + efavirenz (EFV) and subsequent treatment of tenofovir DF (TDF) + ABC/3TC non-responders (NRs): ESS30009 planned 24 week analysis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 2004 [Abstract H-567].
32. McColl DJ, Margot NA, Lu B, Cheng AK, Miller MD. Lack of resistance to tenofovir DF at week 48 and impact of baseline resistance mutations on treatment response in study 934. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil, July 2005 [Poster TuPp0305].
33. Grant RM, Hecht FM, Warmerdam M et al. Time trends in primary HIV-1 drug resistance among recently infected persons. J Am Med Assoc 2002; 288: 181-188.
34. Violin M, Cozzi-Lepri A, Velleca R et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18: 227-235.